ENESDENewsletter →
Shotlee
Get the app
📖Complete Guide✅Updated 2026🔬Evidence-Based

Efinopegdutide Guide

Hanmi

Complete guide to Efinopegdutide. Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical.

Download on theApp Store
Get it onGoogle Play
Weight Loss (26 wks)
~9%
Liver Fat
Major ↓
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
EfinopegdutideB12
EFINOPEGDUTIDE
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Efinopegdutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
EfinopegdutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
EfinopegdutideB12
EFINOPEGDUTIDE
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Efinopegdutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
EfinopegdutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

Hanmi\'s GLP-1/Glucagon Dual Agonist

Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical and partnered with MSD (Merck). Its dual mechanism targets both appetite regulation (via GLP-1) and energy expenditure (via glucagon). It has shown particular promise for reducing liver fat, positioning it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis). Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.

02DEEP DIVE

What Is Efinopegdutide?

Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical and partnered with MSD (Merck). Its dual mechanism targets both appetite regulation (via GLP-1) and energy expenditure (via glucagon). It has shown particular promise for reducing liver fat, positioning it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis).

Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.

03WHAT TO TRACK

How It Works

01
🔬
GLP-1 Agonism
Appetite suppression. Improved insulin sensitivity. Blood sugar regulation. Track metabolic data in Shotlee
02
🔬
Glucagon Agonism
Increases energy expenditure. Promotes liver fat breakdown. Boosts calorie burning. Monitor body comp in Shotlee
03
🎯
Liver Focus
Significant liver fat reduction. MASH treatment potential. Dual metabolic attack. Log all results in Shotlee
04
🔬
Why This Matters
By adding glucagon receptor activation to GLP-1 signaling, efinopegdutide increases energy expenditure while reducing appetite — attacking obesity from both sides. The liver fat reduction makes it esp
04KEY NUMBERS

Clinical Data

📈
Weight Loss (26 wks)
0%
💪
Liver Fat
0Major ↓
05MECHANICS

Side Effects

1
Nausea (GI class)
2
Decreased appetite
3
Dose-dependent effects
4
Log symptoms in Shotlee
06WHAT TO TRACK

Vital Protocol FAQs

01
🔬
What is Efinopegdutide?
It is a dual GLP-1 and glucagon receptor agonist developed by Hanmi/MSD, notable for its liver fat reduction capabilities. Track your protocol in Shotlee.
02
🎯
Is it only for liver disease?
No, it is being studied for both obesity and MASH. The dual mechanism benefits weight loss and liver health simultaneously. Use Shotlee to monitor your progress.
07FAQ

Guide FAQs

Complete guide to Efinopegdutide. Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical.

Yes. Shotlee supports tracking Efinopegdutide doses, side effects, and health metrics. It is free to use.

Free · Always

Track Your Efinopegdutide Protocol in Shotlee

Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.

Download on theApp Store
Get it onGoogle Play

📚References & sources

🔗Keep exploring

All Guides
→
Trackers
→
Compare
→
Start tracking